Merck & Company, Inc. · NYSE:MRK
Merck & — Investor Day (October 2026)
27 slides from Merck &'s investor day presentation, Oct 26, 2026
Slide 1: ESMO Investor Event
October 26, 2026 ESMO Investor Event Merck & Co., Inc., Rahway, N.J., USA 1
Slide 2: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These state
Slide 3: Agenda
Opening Remarks | Dr. Eliav Barr ESMO Data Highlights | Dr. Marjorie Green Agenda Closing Remarks | Dr. Eliav Barr Q&A | All 3
Slide 4: Opening Remarks
Opening Remarks Dr. Eliav Barr Senior Vice President, Head of Global Clinical Development & Chief Medical Officer 4
Slide 5: Sustaining durable leadership in oncology through two strategic objectives
Sustaining durable leadership in oncology through two strategic objectives outlined in 2021 MAXIMIZE DIVERSIFY impact and move into earlier stage pipeline with novel mechanisms disease including with KEYTRUDA QLEX LEVERAGE KEYTRUDA as foundation to advance standard of care 5
Slide 6: Uniquely positioned to advance cancer care with differentiated portfolio and pipeline
Uniquely positioned to advance cancer care with differentiated portfolio and pipeline Immuno-oncology Precision Molecular Targeting Tissue Targeting Boost anti-tumor immune Impact pathways that can drive Increase cancer cell sensitivity responses cancer growth with ADCs and immune cell engagers 2 3
Slide 7: Strategy to maximize benefit for patients with unambiguous efficacy and biomarker enrichment
Strategy to maximize benefit for patients with unambiguous efficacy, informed combinations, biomarker enrichment, curative intent settings Combinable agents Biomarkers Earlier-stage disease Best outcomes achieved when Predictive biomarkers enable Early treatment improves non-cross resistant therapie
Slide 8: ESMO Data Highlights
ESMO Data Highlights Dr. Marjorie Green Senior Vice President, Head of Oncology Global Clinical Development 8
Slide 9: Potentially practice changing data across broad oncology pipeline at ESMO
Potentially practice changing data across broad oncology pipeline at ESMO ESMO at a glance Presidential Symposia Intismeran autogene1 >90 3 − INTerpath-001 (adjuvant stage IIB-IV melanoma) submitted Presidential abstracts Symposia Sac-TMT − TroFuse-005 (post anti PD-1/L1 and platinum chemotherapy en
Slide 10: Sac-TMT designed as cornerstone ADC with potential best-in-class profile
Sac-TMT designed as cornerstone ADC with potential to deliver best-in- class profile across multiple tumors Sac-TMT Mechanism of Action • TROP2-directed ADC with belotecan-derived topoisomerase I inhibitor payload • Unique bifunctional linker designed to maximize payload delivery to tumor cells − Ir
Slide 11: TroFuse-005 aims to address significant remaining unmet need in endometrial cancer
TroFuse-005 aims to address significant remaining unmet need in endometrial cancer Endometrial cancer TroFuse-005 Study Design • 6th most common cancer in women with increasing Key Eligibility incidence and mortality Criteria1 • Persistent racial disparities with >2x mortality rate for black women R
Slide 12: TroFuse-005 is the first positive global Phase 3 study for sac-TMT
TroFuse-005 is the first positive global Phase 3 study for sac-TMT from expansive TroFuse clinical development program • Demonstrated statistically significant and clinically meaningful improvement in OS and PFS PFS in patients with advanced or recurrent endometrial by BICR cancer who received plati
Slide 13: Results from OptiTROP-Lung06 strengthens evidence for sac-TMT in 1L NSCLC
Results from OptiTROP-Lung061 strengthens evidence for sac-TMT in 1L NSCLC • Demonstrated statistically significant and clinically meaningful improvement in PFS as first PFS line treatment for certain patients with by BICR nonsquamous PD-L1-negative NSCLC • Deeper and longer duration of response − D
Slide 14: Differentiated Phase 3 TroFuse development program with first mover opportunities
Differentiated Phase 3 TroFuse development program with first mover opportunities to address unmet needs across common tumor types Gynecologic Breast NSCLC GI GU Endometrial Ovarian Cervical HR+ TNBC EGFRwt EGFRm Gastric Bladder TroFuse- 032 Earlier TroFuse- Stage 019 TroFuse- 012 TroFuse- 007 1L Tr
Slide 15: Uniquely positioned to explore promising science of PD-1xVEGF with MK-2010
Uniquely positioned to explore promising science of PD-1xVEGF with MK- 2010 Development considerations MK-2010 combination studies underway • Advantaged company to fully explore potential of PD-1xVEGF axis REJOICE- Study/protocol # MK-2010-003 MK-2010-002 ‒ Leverage PD-1 and VEGF experience to Ovari
Slide 16: Intismeran autogene is an mRNA-based INT, bringing a new era of personalized cancer research
Intismeran autogene is an mRNA-based INT, bringing a new era of personalized cancer research Intismeran Mechanism of action • Investigational lipid encapsulated T-Cell Activation Tumor Destruction mRNA based individualized neoantigen therapy • Consists of an mRNA that encodes neoantigens designed sp
Slide 17: INTerpath-001 is the first positive Phase 3 study for an mRNA-based individualized neoantigen therapy
INTerpath001 is the first positive Phase 3 study for an mRNA-based individualized neoantigen therapy • Demonstrated statistically significant and clinically meaningful improvement in RFS and RFS DMFS DMFS as adjuvant treatment in certain patients with completely resected stage IIB- IV melanoma • Fav
Slide 18: Pre-specified piecewise sensitivity analysis shows benefit was greater after six months
Pre-specified piecewise sensitivity analysis shows benefit was greater after six months RFS DMFS • Delayed separation of RFS and DMFS 0-6 months: HR 0.99 (95% CI 0.66–1.49) 0-6 months: HR 1.01 (95% CI 0.58–1.79) • RFS and DMFS benefit greater after six >6 months: HR 0.50 (95% CI 0.34–0.73) >6 months
Slide 19: Advancing a robust late-phase development plan for intismeran
Advancing a robust late-phase development plan for intismeran Phase 1 Phase 2 Phase 3 Status INTerpath-001 (adjuvant melanoma) POSITIVE DATA INTerpath-002 (adjuvant stage II-IIIB NSCLC) COMPLETED ENROLLMENT INTerpath-009 (perioperative stage II-IIIB NSCLC) RECRUITING INTerpath-014 (adjuvant stage I
Slide 20: Closing Remarks
Closing Remarks Dr. Eliav Barr Senior Vice President, Head of Global Clinical Development & Chief Medical Officer 20
Slide 21: Two potential important approvals next year
Two potential important approvals next year Sac-TMT FDA accepted for priority review PDUFA June 15th BLA for patients with advanced or recurrent endometrial cancer who have received prior platinum- based chemotherapy and anti-PD-1/L1 immunotherapy 2027 Intismeran autogene1 FDA Breakthrough Therapy D
Slide 22: Approaching substantial registration-enabling opportunity set across diversified oncology pipeline
Approaching substantial registration-enabling opportunity set across diversified oncology pipeline Tissue Targeting Precision Molecular Immuno-oncology sacituzumab tirumotecan opevesostat intismeran autogene1 (sac-TMT) (TROP2 ADC) (CYP11A1i) (V940) TroFuse-011 KANDLELIT-013 ifinatamab deruxtecan1 ca
Slide 23: Q&A
Q&A Dr. Eliav Barr Dr. Marjorie Green Peter Dannenbaum SVP, Head of Global SVP, Head of Oncology SVP, Investor Relations Clinical Development & Global Clinical Chief Medical Officer Development 23
Slide 24: Appendix
Appendix 24
Slide 25: Acronyms
Acronyms 1L = First-Line HER2 = Human epidermal growth factor receptor 2 NSCLC = Non-small cell lung cancer ADC = Antibody-drug conjugate HER3 = Human epidermal growth factor receptor 3 OS = Overall survival B7-H3 = B7 homolog 3 HLA = Human leukocyte antigen PD-1 = Programmed cell death protein 1 BI
Slide 26: Eliav Barr, MD
Eliav Barr, MD Senior Vice President, Head of Global Clinical Development, Chief Medical Officer Dr. Eliav Barr is senior vice president and head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. He leads all late-stage clinical development for Merck’s human he
Slide 27: Marjorie Green, MD
Marjorie Green, MD Senior Vice President, Head of Oncology Global Clinical Development Dr. Marjorie Green is senior vice president and head of oncology global clinical development at Merck Research Laboratories. Marjorie joined Merck from Seagen, where she was senior vice president and head of late-